Navigation Links
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Date:1/27/2009

KENILWORTH, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that it has completed patient enrollment in the boceprevir HCV SPRINT-2 study, a pivotal Phase III study in treatment-naive patients. Together with the HCV RESPOND-2 study, a pivotal Phase III study in patients who failed prior treatment that completed enrollment in November 2008, the Company has fully enrolled its registration studies for boceprevir, its lead investigational oral hepatitis C protease inhibitor. A total of more than 1,500 patients were enrolled in these studies at U.S. and international sites.

"We believe boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "We are very encouraged by the boceprevir study results reported to date and look forward to the completion of these registration studies." The Company expects to complete the studies in mid-2010.

Schering-Plough previously reported Phase II study results from Part I of the HCV SPRINT-1 study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In that study, a 48-week boceprevir regimen achieved a 75 percent SVR rate in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (P/R lead-in, n=103). This represents a near doubling of the 38 percent SVR rate for patients in the control group receiving 48 weeks of PEGINTRON and REBETOL alone (n=104) (ITT).(1,2) In a 28-week boceprevir P/R lead-in regimen, the SVR rate was 56 percent (n=103). Importantly, for patients who received the boceprevir P/R lead-in regimen and had rapid virologic response (RVR), defined as undetectable
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... India (PRWEB) July 31, 2014 RankingBySEO, ... service for those individuals and organizations against whom negative ... as ‘Remove Negative Comments Service’. , About the ... “We have officially announced the service now, but we ... rid of negative comments for several years.” , On ...
(Date:7/31/2014)... 31, 2014 T.E.N., a technology ... honored finalists and winners Wednesday evening, July 30, ... Awards Gala at the Westin St. Francis in ... information security for the BlackLine Systems, was selected ... Award winner for the ISE® West Region. As ...
(Date:7/31/2014)... Steven Reinberg HealthDay Reporter ... regulation of electronic cigarettes isn,t warranted based on current ... contrary, allowing e-cigarettes to compete with regular cigarettes might ... reviewing 81 prior studies on the use and safety ... suggests that there is a potential for smokers to ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 ... Marketing Company, has introduced a new service named ... , Ethane Web Technologies has designed the service ... of clients and Java Development service being provided ... the company a confidence to promise outstanding Java ...
(Date:7/31/2014)... 2014 Bedros Keuilian’s Fit Body Boot Camp ... other countries. At his annual Fitness Business Summits, some of ... their marketing strategies. But in his latest blog post, he ... marketing a personal training business is to create free ... personal trainer has a certain area that they really feel ...
Breaking Medicine News(10 mins):Health News:RankingBySEO Launches a New Service ‘Remove Negative Comments’ 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 3
... difference in effectiveness of 5 drugs currently available , , ... that any one of the five drugs available in ... the others, says an American College of Physicians (ACP) ... just issued a new guideline on drug treatment of ...
... Publishing, an award-winning interactive, visual content developer, today ... the first free, Web-based 3-D interactive model of ... educators, and health and medical professionals, The Visible ... how the human body works. It will also ...
... ANNAPOLIS, Md., March 4 Dozens of ... gathered in Annapolis today as,the General Assembly ... regulations, protections against identity theft, and the ... visited legislators,offices and attended committee hearings on ...
... Market Segments, CHICAGO, March 4 Throw ... Financial services firms, insurers, and,healthcare payors admit they ... to serve baby boomers, who will control some ... who make up the wealthiest generation in history, ...
... CA A nuclear receptor protein, known for controlling ... powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice ... research by scientists at the Salk Institute for Biological ... , Their findings, reported in this weeks online edition ...
... swayed by adolescent drug use trends , , TUESDAY, March 4 ... boys are more likely to give up the habit if ... no matter what, new research shows. , The findings ... to the wider world,s embrace of illegal drugs, said study ...
Cached Medicine News:Health News:Groups Issue New Dementia Drug Guidelines 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Utilities, Long Term Care Bills at Center of 'AARP Day In Annapolis' 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 3Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 4Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 5Health News:New potential drug target for the treatment of atherosclerosis 2Health News:New potential drug target for the treatment of atherosclerosis 3Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2
(Date:7/31/2014)... , 31 juli 2014 De Pfizer Clinical ... rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor medewerking ... gevestigde PCRU is één van twee onderzoekseenheden ... ideaal levens te verbeteren door de ontdekking en ontwikkeling ... PCRU op zoek naar mannen en vrouwen van Japanse ...
(Date:7/30/2014)... Mich. , July 30, 2014 Advanced Photonix ... quarter (ending June 27, 2014) financial results on Monday, August ... be released after the close of the market and the ... the results at 4:30 p.m. EDT on the same day. ... Kurtz (CEO and Director), Rob Risser (COO ...
(Date:7/30/2014)... July 30, 2014  Cepheid (Nasdaq: ... contract with Premier will end on September 30, ... will be able to continue their relationship with ... MedAssets, Novation, and ROi, in addition to the ... Cepheid. "Cepheid has always recognized and ...
Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3
... Advanced Sterilization Products (ASP) announced today the ... GLOSAIR™ Healthcare Environmental Decontamination – that provides effective, ... operating suites to reduce the risk of patient ... scientific consensus that the patient environment is a ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Depression ... http://www.reportlinker.com/p0564398/Product-Profiles-Depression---Next-generation-vies-for-second-line-patients.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... Patents for the current market-leading depression brands ...
Cached Medicine Technology:ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 2ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 3ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 4ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 5Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 2Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 3Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 4Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 5
... Sickle-Chex is a positive and negative ... presence of Hemoglobin S in solubility tests ... Streck SICKLEDEX and other manufacturers' solubility ... plastic squeeze dropper vial. The vial dispenses ...
... whole blood hematology control manufactured specifically for ... and the Coulter AcT5diff instruments. The composition ... cell differential, positioning the populations within the ... The product offers 105-day closed-vial stability and ...
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Medicine Products: